RET and neoplasm: This is in line with the findings of Lambertz et al. and Cazes et al. [21,24], who observed increased Ret mRNA in ALK/MYCN versus MYCN tumor models, and could show that ALK-amplified or mutant cell lines, as well as tumors, were sensitive to the vandetanib tyrosine kinase inhibitor (TKI), which inhibits RET among other kinase targets.